Back to Search Start Over

[Growth hormone treatment of familial hypophosphatemic rickets].

Authors :
Saggese G
Baroncelli GI
Barsanti S
Source :
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie [Arch Pediatr] 1998; Vol. 5 Suppl 4, pp. 360S-363S.
Publication Year :
1998

Abstract

X-linked hypophosphatemic rickets (XLHR) is frequently associated with growth retardation and short adult stature, even with an appropriate conventional treatment associating phosphate and calcitriol or 1 alpha-hydroxyvitamin D. Its pathogenesis is unclear; growth hormone (GH) secretion is usually normal. Six children with XLHR and growth retardation were treated with GH during 6 years. In addition, they received the conventional treatment. At the beginning of the treatment mean age was 7.8 +/- 1.8 years, and height mean Z score was -3.4 +/- 0.5. A control group was composed of six children with XLHR (age: 7.9 +/- 2.5 years) receiving the conventional treatment only. Under GH treatment statural growth was improved, with significant increase in Z score and predicted adult height; the height gain was significantly higher in the GH treated group as compared with the group receiving the conventional treatment only. In addition, radial bone mineral density increased significantly under GH treatment. GH treatment thus appears to be a useful treatment to improve statural growth in children with XLHR.

Details

Language :
French
ISSN :
0929-693X
Volume :
5 Suppl 4
Database :
MEDLINE
Journal :
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
Publication Type :
Academic Journal
Accession number :
9853084
Full Text :
https://doi.org/10.1016/s0929-693x(99)80191-2